Mood Disorders

Phase 3 study of TC-5214 for major depressive disorder (MDD)

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).